CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment [Yahoo! Finance]
CG Oncology, Inc. - Common stock (CGON)
Company Research
Source: Yahoo! Finance
price target on CG Oncology to $79 from $56, while maintaining an Overweight rating on the shares. Earlier in August, CG Oncology announced significant clinical advancements in its bladder cancer pipeline and financial results for Q2 2025. The company is focused on developing cretostimogene grenadenorepvec, which is an investigational oncolytic immunotherapy for Non-Muscle Invasive Bladder Cancer/NMIBC. Management's outlook is supported by a strong cash position and a favorable legal outcome that together are expected to fund operations into the first half of 2028. CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment Clinical trial updates highlighted promising data from the BOND-003 Cohort C trial for high-risk NMIBC patients who are unresponsive to BCG treatment. The company also initiated the CORE-008 Cohort CX trial, which is evaluating the combination of cretostimogene and gemcitabine in high-risk NMIBC patients. Upc
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CGON
News
- New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder CancerGlobeNewswire
- CG Oncology Announces New Board Member and Board Transition [Yahoo! Finance]Yahoo! Finance
- CG Oncology Announces New Board Member and Board TransitionGlobeNewswire
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting [Yahoo! Finance]Yahoo! Finance
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual MeetingGlobeNewswire
CGON
Earnings
- 11/14/25 - In-Line
CGON
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 3
- 11/26/25 - Form 8-K
- CGON's page on the SEC website